

*Sub D1
Contd*

(i) administering said bioactive agent to said patient, by a route of administration sufficient to achieve a predetermined concentration of said bioactive agent within the vasculature of said selected tissue;

C1

(ii) administering a vesicle composition to said patient, by continuous intravascular infusion for a time sufficient to achieve a predetermined concentration of said vesicle composition within the vasculature of said selected tissue, wherein said vesicle composition comprises, in an aqueous carrier, vesicles comprising lipids, proteins or polymers and a gas or gaseous precursor; and

(iii) applying ultrasonic energy to said selected tissue in an amount sufficient to produce cavitation or rupture of said vesicles, wherein said cavitation or rupture of said vesicles induces an increased delivery of said bioactive agent from said vasculature to said selected tissue.

117. (Amended) A method according to Claim 116 wherein said bioactive agent is administered to said patient by continuous intravascular infusion.

Sub D2

164. (Amended) A method for enhancing the delivery of a bioactive agent to a selected tissue in a patient, said method comprising:

C2

(i) administering said bioactive agent to said patient, by a route of administration sufficient to achieve a predetermined concentration of said bioactive agent within the vasculature of said selected tissue;

(ii) administering an acoustically active composition to said patient, by continuous intravascular infusion for a time sufficient to achieve a predetermined concentration of said acoustically active composition within the vasculature of said selected tissue; and

(iii) applying ultrasonic energy to said selected tissue in an amount sufficient to activate said acoustically active composition,